IGC Pharma, Inc. 8-K

What Happened
IGC Pharma, Inc. (IGC) filed an 8‑K (dated July 6, 2026) disclosing Stock Purchase Agreements dated June 30, 2026 with CEO Ram Mukunda and Vice President and Principal Financial Officer Claudia Grimaldi. Instead of cash, each executive received common stock at $0.27 per share in exchange for cancellation of amounts the company owed them. The company issued 2,226,475 shares to Mr. Mukunda to cancel $601,148 of obligations (including about $283,639 of personal cash advances) and issued 2,048,378 shares to Ms. Grimaldi to cancel $553,062 of obligations (including about $268,723 of personal cash advances). The transactions involved no cash payments and were approved in advance by the independent directors and the Audit Committee, with interested directors recused.

Key Details

• Total shares issued: 4,274,853 (2,226,475 to Ram Mukunda; 2,048,378 to Claudia Grimaldi).
• Purchase price: $0.27 per share.
• Total obligations extinguished: $1,154,210 ($601,148 to Mukunda; $553,062 to Grimaldi).
• Agreements dated June 30, 2026; 8‑K filed July 6, 2026; form of Stock Purchase Agreement filed as Exhibit 10.1.
• Independent directors and the Audit Committee approved the transactions; interested directors were recused (noted for Rule 16b‑3 purposes).

Why It Matters
The transactions reduce IGC’s outstanding liabilities by $1,154,210 without using cash, shifting that value into stockholders’ equity and issuing 4.27 million new shares. That increases the company’s share count and therefore changes existing ownership percentages (i.e., dilution of current holders). The pre-approval by independent directors and the Audit Committee, with recusal of interested parties, indicates the company followed internal governance steps and noted compliance considerations under Rule 16b‑3. Investors should watch subsequent filings for updated total shares outstanding and the impact on the company’s balance sheet and per‑share metrics.